BRDG1 ELISA Kits

Bromodomain-containing protein 7 (BRD7) is a member of the bromodomain-containing protein family mainly localized in the nuclear compartment of the cell. The closely related BRDs, BRD7 and BRD9 are part of the SWI/SNF nucleosome_remodeling complex, which plays a crucial role regulating gene expression programs, including the expression of inflammatory genes. The quinolone_fused lactam LP99 is now reported as the first potent and selective inhibitor of the BRD7 and BRD9 bromodomains. Also, BRDs are protein interaction modules that selectively recognize __N_lysine acetylation motifs, a key event in reading the posttranslational modifications that constitute the epigenetic code. BRD_containing protein 7 (BRD7), has a proposed tumor suppression function through regulation of p532 and PI3K. Furthermore, BRD7 has been shown to be required for BRCA1_dependent transcription and BRD7 polymorphism has been linked to an increased risk of pancreatic cancer.

BRD7 is a transcriptional co-activator for p53 modulating histone acetylation, p53 acetylation and promoter activity in p53 target genes. Previous studies show that BRD7 is down-regulated in a number of cancer types and this may correlate with clinical outcomes. A study investigated the expression, CpG island methylation and sub-cellular localization of BRD7 in Breast cancer (BC) cell lines and clinical cases and thereby assessed its prognostic significance by correlating with clinicopathologic features and time-dependent clinical outcomes. Results show that BRD7 was expressed at levels similar to normal breast epithelium and the CpG island unmethylated in all 13 cell lines. The study concluded that BRD7 is a strong candidate for breast cancer tumor suppressor and prognostic biomarker.